Coronavirus Disease 2019 (COVID-19) vaccine by China National Biotec Group for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Research shows how resistant starch could slow down progression of non-alcoholic fatty liver disease

The prebiotic resistant starch could play an important role in the treatment of non-alcoholic fatty liver disease (NAFLD) in the future.

September 5, 2023

FDA approves subcutaneous version of Bristol Myers’ Opdivo

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 28, 2024

Novartis wanted just one drug from MorphoSys before upping bid for whole company, document reveals

Before Novartis went all in on MorphoSys for $2.9 billion in February, the Swiss pharma giant initially wanted just one key piece from the German

April 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.